Money Compass

Money Compass

ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

SUZHOU, China, June 10, 2025 /PRNewswire/ -- ImmVira, a global leading clinical-stage biotechnology company focused on the development of next-generation novel oncolytic immunotherapy for treatment of cancer, announced that the first...

Read more
Page 1637 of 2084 1 1,636 1,637 1,638 2,084

Welcome Back!

Login to your account below

Retrieve your password

Please enter your username or email address to reset your password.